iSTAR Medical Expands Leadership Team in the U.S.
iSTAR Medical, a prominent innovator in medtech focused on transformative solutions for eye care, has announced important changes to its leadership team. The recent appointments of Richard (Rick) Beckman, M.D. as Chief Medical Officer and Kristine (Kris) Curtiss as Vice President of Clinical Affairs represent a significant move in the company’s strategy to enhance its footprint in the U.S. market.
Enhancements to Leadership
The appointment of Rick Beckman as Chief Medical Officer marks a pivotal moment for the company. With a wealth of experience in clinical, regulatory, and medical affairs, Rick is poised to significantly advance iSTAR Medical's clinical initiatives. A board-certified ophthalmologist with a specialization in glaucoma, Rick previously held the role of CMO at Adverum and brings a rich background in healthcare and biotechnology.
Legacy of Previous Leadership
Kaweh Mansouri, M.D., who has served as CMO, is transitioning to focus on his role as Executive Vice President of the World Glaucoma Association. He will remain involved with iSTAR Medical as a Senior Medical Advisor. His contributions have been instrumental in establishing the company’s reputation, particularly with the innovative MINIject product.
Kris Curtiss Joins the Medical Team
Kris Curtiss has been appointed as Vice President of Clinical Affairs, bringing over 20 years of extensive clinical research experience to the position. In her new role, Kris will oversee iSTAR Medical’s STAR-V trial and work closely with Rick Beckman. Her strong background in leadership roles at various biotech and medical device companies has well-prepared her for this position.
Insights from Key Executives
Michel Vanbrabant, CEO of iSTAR Medical, expressed his excitement regarding these appointments, stating, "We are thrilled to welcome Rick and Kris to our leadership team. Their combined expertise in the medical field will be vital in delivering advanced eye care solutions to a larger patient population. We also extend our gratitude to Kaweh for his significant contributions that helped establish MINIject as a trusted treatment option for glaucoma patients."
About iSTAR Medical and MINIject®
iSTAR Medical is committed to providing innovative solutions for eye care. Their flagship device, MINIject®, has received approval in Europe for the treatment of open-angle glaucoma, a leading cause of blindness. The device's unique tissue-integrating features offer a safer and more effective treatment option for patients. Currently, iSTAR Medical is pursuing market approval in the U.S.
Strategic Collaborations
In July 2022, iSTAR Medical formed a strategic partnership with AbbVie (NYSE: ABBV) aimed at enhancing the reach and availability of MINIject. This collaboration seeks to deliver advanced glaucoma treatments to a broader patient population while leveraging AbbVie’s extensive eye care portfolio.
Understanding Glaucoma
Glaucoma is a progressive eye disease that affects millions globally, with primary open-angle glaucoma being the most common type. Effective management often involves lowering intraocular pressure, which can be accomplished through medication or surgical procedures. However, the challenges associated with traditional treatments underscore the necessity for innovative solutions like MINIject®, which promises a safer profile and potentially improved outcomes for patients.
Frequently Asked Questions
What recent appointments were made at iSTAR Medical?
Rick Beckman was appointed as Chief Medical Officer, and Kris Curtiss joined as Vice President of Clinical Affairs.
What is the primary product of iSTAR Medical?
iSTAR Medical's primary product is MINIject®, designed for the treatment of open-angle glaucoma.
Why are the new appointments significant for iSTAR Medical?
These appointments are critical as they bring extensive clinical and regulatory experience needed to enhance iSTAR Medical's presence in the U.S. market.
Who will be advising iSTAR Medical in the future?
Kaweh Mansouri, who is stepping down as CMO, will continue to consult as a Senior Medical Advisor to the company.
What is the goal of iSTAR Medical's partnership with AbbVie?
The partnership aims to provide broader access to MINIject® and support the development of innovative glaucoma treatments globally.
